AN4005
Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
288 Active assets in the Advanced Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINBLASTINE Intensity Therapeutics, Inc. | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation | Phase 4 | BBB |
BLEOMYCIN Shandong Provincial Hospital | Phase 4 | BB |
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
(+)-VINCRISTINE Beth Israel Deaconess Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
AN4005 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →